Angiotensin II receptor blocker combinations: From guidelines to clinical practice

Blood Pressure

Volumn 21, Issue 2, 2012, Pages 73-81

  Narkiewicz, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

amlodipine; angiotensin II type receptor blocker; guidelines; hydrochlorothiazide; hypertension; olmesartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLICLAZIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; HYPOTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; TETRAZOLES;

EID: 84859051396     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2011.598700     Document Type: Review

References (62)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187. (Pubitemid 46924065)
2. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1153.
3. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of european guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
4. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27:923-934.
5. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304: 61-68.
6. Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
7. Wang YR, Alexander GC and Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167:141-147. (Pubitemid 46151611)
8. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
9. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4: 393-404. (Pubitemid 35469393)
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
11. Wald DS, Law M, Morris JK, Bestwick JP and Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290-300.
12. Law MR, Morris JK and Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
13. Erdine S. Compliance with the treatment of hypertension: The potential of combination therapy. J Clin Hypertens (Greenwich). 2010;12:40-46.
14. Krousel-Wood M, Thomas S, Muntner P and Morisky D. Medication adherence: Akey factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357-362. (Pubitemid 38916494)
15. Schroeder K, Fahey T and Ebrahim S. How can weimprove adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722-732. (Pubitemid 38478694)
16. WHO. Adherence to long-term therapies: Evidence for action. http://www.who.int/chp/knowledge/publications/adherence-full-report.pdf. 2003. Accessed: 21 September 2010.
17. Claxton AJ, Cramer J and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310. (Pubitemid 32804122)
18. Gupta AK, Arshad S and Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension. 2010;55:399-407.
19. Oparil S, Melino M, Lee J, Fernandez V and Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double - blind, 12-week, parallel-group study. Clin Ther. 2010; 32:1252-1269.
20. Calhoun DA, Lacourciere Y, Chiang YT and Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trial. Hypertension. 2009;54:32-39.
21. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
22. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366: 895-906. (Pubitemid 41265663)
23. PROGRESS Collaborative Study Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
24. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370: 829-840. (Pubitemid 47362321)
25. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898. (Pubitemid 351620109)
26. J ulius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.
27. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vsa noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil - Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290:2805-2816.
28. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine orhydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
29. Law MR, Wald NJ, Morris JK and Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ. 2003;326: 1427.
30. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, orboth in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
31. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P and Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624-1630.
32. Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin - angiotensin system in the hypertension paradigm. Clin Exp Hypertens [Research Support, Non-U.S. Gov't Review]. 2010;32:35-42.
33. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: A review of the factorial-design studies. J Clin Hypertens [Research Support, Non-U.S. Gov't Review]. 2004;6:569-577.
34. Ram CV. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: A review of factorial-design studies. Current medical research and opinion [Review]. 2009;25:177-185.
35. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M and Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther. 2002;71:68-76. (Pubitemid 34124040)
36. Coltamai L, Maillard M, Simon A, Vogt B and Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens. 2010;28:520-526.
37. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999;33:850-855. (Pubitemid 29140445)
38. Fabia MJ, Abdilla N, Oltra R, Fernandez C and Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25: 1327-1336. (Pubitemid 46924066)
39. Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR and Burnier M. Sustained 24-hour blockade of the renin -angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensinconverting enzyme inhibitor. Clin Pharmacol Ther. 2005; 78:501-507. (Pubitemid 41698904)
40. Jones MR, Sealey JE and Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. American Journal of Hypertension. 2007;20:907-916. (Pubitemid 47176356)
41. Smith DH, Dubiel R and Jones M. Use of24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:41-50.
42. Brunner HR, Stumpe KO and Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23:419-430. (Pubitemid 36920514)
43. Neutel JM. Prescribing patterns in hypertension: The emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Current Med Res Opin [Research Support, Non-U.S. Gov't Review]. 2008;24:2389-2401.
44. Fogari R, Taddei S, Holm-Bentzen M, Baszak J, Melani L and Schumacher K. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: A randomized, doubleblind, parallel-group, multicentre, multinational, phase III study. Clin Drug Investig. 2010;30:581-597.
45. Oparil S, Chrysant SG, Kereiakes D, Xu J, Chavanu KJ, Waverczak W, et al. Results of an olmesartan medoxomilbased treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich). 2008;10:911-921.
46. Volpe M, Brommer P, Haag U and Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009; 29:11-25.
47. Rump LC and Sellin L. Combination therapy for hypertension: Focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide. Expert Opin Pharmacother. 2010;11: 2231-2242.
48. Chrysant S, Melino M, Karki S, Lee J and Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604. (Pubitemid 351680489)
49. Heagerty AM, Laeis P and Haag U. Olmesartan medoxomil/ amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy - additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens. 2009;27 Suppl 4 S283.
50. Chrysant SG, Weber MA, Wang AC and Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17:252-259. (Pubitemid 38293331)
51. Chrysant SG, Chavanu KJ and Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: Secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs. 2009;9:241-251.
52. Rump LC, Girerd X, Sellin L and Stegbauer J. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens. 2010;Epub ahead of print.
53. Kereiakes DJ, Neutel J, Stoakes KA, Waverczak WF, Xu J, Shojaee A, et al. The effects of an olmesartan medoxomilbased treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich). 2009;11:411-421.
54. Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J and Shojaee A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin. 2010;26:721-728.
55. Punzi H, Neutel JM, Kereiakes DJ, Shojaee A, Waverczak WF, Dubiel R, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis. 2010;4:209-221.
56. Ram VS, Sachson RA, Qian C, Patel M and Stoakes KA. Effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension, type 2 diabetes, and metabolic syndrome. J Clin Hypertens. 2010;12:A96.
57. Haller H, Ito S, Izzo JL, Jr., Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New Engl J Med. 2011;364:907-917.
58. US Food and Drug Administration. FDA Drug Safety Communication: Safety Review Update of Benicar (olmesartan) and cardiovascular events. http://www.fda.gov/Drugs/Drug-Safety/ucm251268.htm; 2011.
59. Chrysant S, Melino M, Fernandez V, Lee J and Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM) + amlodipine besylate (AML) + hydrochlorothiazide (HCTZ) in patients with hypertension: Analysis by age and gender. J Clin Hypertens. 2010;12Suppl 1:A30-A31.
60. Izzo J, Melino M, Fernandez V, Lee J and Heyrman R. 24-hour efficacy and safety of full-dose, triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide. J Clin Hypertens. 2010;12 Suppl 1:A34-A35.
61. Ram CV, Sachson R, Littlejohn T, Qian C, Shojaee A, Stoakes KA, et al. Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Am J Cardiol. 2011;107:1346-1352.
62. Weir MR, Hsueh W, Nesbitt SD, Littlejohn TJ, Graff A, Shojaee A, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide. J Clin Hypertens. 2011;Published ahead of print (5 FEB 2011, DOI: 10.1111/j.1751-7176.2011.00437).